Murine bone marrow–derived mesenchymal stem cells as vehicles for interleukin‐12 gene delivery into Ewing sarcoma tumors

Abstract

Three aromatic diamine‐based benzoxazines were successfully prepared by a facile, clean, one‐pot procedure from 1,4‐phenylenediamine (1), 4,4′‐diaminodiphenyl ether (2), and 4,4′‐diaminodiphenyl methane (3), respectively. Their structures were confirmed by NMR spectra and single crystal diffractogram. The effect of the reactivity of diamines on the purity of the resultant benzoxazines was discussed. The resultant benzoxazines were applied as hardeners for cresol novolac epoxy (CNE). The processing window, the latent curing characteristic, and the miscibility of benzoxazine/CNE systems were discussed. Compared with diamines (1 and 3), (1 and 3)‐based benzoxazines show latent curing characteristic as epoxy hardeners, and wide processing windows can be obtained. Compared with diamine (2) which is immiscible with CNE in the molten state, (2)‐based benzoxazine shows good miscibility with CNE. Dynamic mechanical analysis shows the Tgs of the benzoxazine/CNE thermosets are as high as 242–243 °C. Thermogravimetric analysis shows the outstanding thermal stability of the resultant thermosets. © 2010 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 48: 2430–2437, 2010

Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy

“…Others reported the use of BM and cord blood MSC as drug delivery systems (1,2,(41)(42)(43)(44)(45)(46)(47). Dealing with AD-MSC, these cells have been recently used as cancer therapy tools to vehicle prodrug-converting enzyme (13); however, to our knowledge, our strategy represents the very first example of cancer gene therapy based on AD-MSC directly producing a potent proapoptotic agent, such as TRAIL.…”

Application of Stem Cells in Targeted Therapy of Breast Cancer: A Systematic Review

“…MSCs migrate to sites of tumorigenesis and are utilized as efficient cellular vehicle for the targeted delivery anti-neoplastic therapy to both primary tumors and their metastases (El-Haibi and Karnoub, 2010). Several preclinical studies support the basis for genetically modified MSC to deliver therapeutics to tumor sites; include glioma, melanoma, Kaposi's sarcoma, Ewing sarcoma, as well as carcinomas of the colon, ovary, breast (Studeny et al, 2004;Nakamizo et al, 2005;Khakoo et al, 2006;Komarova et al, 2006;Karnoub et al, 2007;Menon et al, 2007;Coffelt et al, 2009;Duan et al, 2009;El-Haibi and Karnoub, 2010). Despite these approaches, the basic mechanisms involved in the homing of MSCs to sites of malignant growth are still only partially defined.…”

Stem cell technology and engineering for cancer treatment

“…Stem cells are also utilized to delivery immunestimulatory cytokines including IL-12 (Duan et al, 2009;Eliopoulos et al, 2008;Gao et al, 2010), IL-21 (Hu et al, 2011), IL-24 , TNF-α (Shahrokhi et al, 2013), and IFN-γ (Bitsika et al, 2012). TRAIL (tumor necrosis factor related apoptosis induced ligand) (Shahrokhi et al, 2013) , nanoparticles (Gao et al, 2013) and anti-angiogenic factors (Ghaedi et al, 2011).…”